German S3-guidelines on the treatment of psoriasis vulgaris (short version).

Standard

German S3-guidelines on the treatment of psoriasis vulgaris (short version). / Nast, A; Boehncke, W H; Mrowietz, U; Ockenfels, H M; Philipp, S; Reich, K; Rosenbach, T; Sammain, A; Schlaeger, M; Sebastian, M; Sterry, W; Streit, V; Augustin, Matthias; Erdmann, R; Klaus, J; Koza, J; Müller, S; Orzechowski, H D; Rosumeck, S; Schmid-Ott, G; Weberschock, T; Rzany, B; Gesellschaft, Deutsche Dermatologische; Dermatologen, Berufsverband Deutscher.

in: ARCH DERMATOL RES, Jahrgang 304, Nr. 2, 2, 2012, S. 87-113.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ZeitschriftenaufsatzForschungBegutachtung

Harvard

Nast, A, Boehncke, WH, Mrowietz, U, Ockenfels, HM, Philipp, S, Reich, K, Rosenbach, T, Sammain, A, Schlaeger, M, Sebastian, M, Sterry, W, Streit, V, Augustin, M, Erdmann, R, Klaus, J, Koza, J, Müller, S, Orzechowski, HD, Rosumeck, S, Schmid-Ott, G, Weberschock, T, Rzany, B, Gesellschaft, DD & Dermatologen, BD 2012, 'German S3-guidelines on the treatment of psoriasis vulgaris (short version).', ARCH DERMATOL RES, Jg. 304, Nr. 2, 2, S. 87-113. <http://www.ncbi.nlm.nih.gov/pubmed/22350179?dopt=Citation>

APA

Nast, A., Boehncke, W. H., Mrowietz, U., Ockenfels, H. M., Philipp, S., Reich, K., Rosenbach, T., Sammain, A., Schlaeger, M., Sebastian, M., Sterry, W., Streit, V., Augustin, M., Erdmann, R., Klaus, J., Koza, J., Müller, S., Orzechowski, H. D., Rosumeck, S., ... Dermatologen, B. D. (2012). German S3-guidelines on the treatment of psoriasis vulgaris (short version). ARCH DERMATOL RES, 304(2), 87-113. [2]. http://www.ncbi.nlm.nih.gov/pubmed/22350179?dopt=Citation

Vancouver

Nast A, Boehncke WH, Mrowietz U, Ockenfels HM, Philipp S, Reich K et al. German S3-guidelines on the treatment of psoriasis vulgaris (short version). ARCH DERMATOL RES. 2012;304(2):87-113. 2.

Bibtex

@article{bb34823210294bc08375ab35c5e99f73,
title = "German S3-guidelines on the treatment of psoriasis vulgaris (short version).",
abstract = "Psoriasis vulgaris is a common and often chronic inflammatory skin disease. The incidence of psoriasis in Western industrialized countries ranges from 1.5 to 2%. Patients afflicted with severe psoriasis vulgaris may experience a significant reduction in quality of life. Despite the large variety of treatment options available, patient surveys have revealed insufficient satisfaction with the efficacy of available treatments and a high rate of medication non-compliance (Richards et al. in J Am Acad Dermatol 41(4):581-583, 1999). To optimize the treatment of psoriasis in Germany, the Deutsche Dermatologische Gesellschaft (DDG) and the Berufsverband Deutscher Dermatologen (BVDD) have initiated a project to develop evidence-based guidelines for the management of psoriasis first published in 2006 and now updated in 2011. The Guidelines focus on induction therapy in cases of mild, moderate, and severe plaque-type psoriasis in adults. This short version of the guidelines presents the resulting series of therapeutic recommendations, which were based on a systematic literature search and discussed and approved by a team of dermatology experts. In addition to the therapeutic recommendations provided in this short version, the full version of the guidelines includes information on contraindications, adverse events, drug interactions, practicality, and costs, as well as detailed information on how best to apply the treatments described (for full version please see Nast et al. in JDDG Suppl 2:S1-S104, 2011 or http://www.psoriasis-leitlinie.de ).",
keywords = "Adult, Diagnosis, Differential, Germany, Humans, Quality of Life, Patient Compliance, Evidence-Based Medicine, Patient Satisfaction, Expert Testimony, Clinical Protocols, Skin/*pathology, *Drug Therapy, *PUVA Therapy, Psoriasis/*diagnosis/epidemiology/physiopathology/*therapy, Adult, Diagnosis, Differential, Germany, Humans, Quality of Life, Patient Compliance, Evidence-Based Medicine, Patient Satisfaction, Expert Testimony, Clinical Protocols, Skin/*pathology, *Drug Therapy, *PUVA Therapy, Psoriasis/*diagnosis/epidemiology/physiopathology/*therapy",
author = "A Nast and Boehncke, {W H} and U Mrowietz and Ockenfels, {H M} and S Philipp and K Reich and T Rosenbach and A Sammain and M Schlaeger and M Sebastian and W Sterry and V Streit and Matthias Augustin and R Erdmann and J Klaus and J Koza and S M{\"u}ller and Orzechowski, {H D} and S Rosumeck and G Schmid-Ott and T Weberschock and B Rzany and Gesellschaft, {Deutsche Dermatologische} and Dermatologen, {Berufsverband Deutscher}",
year = "2012",
language = "English",
volume = "304",
pages = "87--113",
journal = "ARCH DERMATOL RES",
issn = "0340-3696",
publisher = "Springer",
number = "2",

}

RIS

TY - JOUR

T1 - German S3-guidelines on the treatment of psoriasis vulgaris (short version).

AU - Nast, A

AU - Boehncke, W H

AU - Mrowietz, U

AU - Ockenfels, H M

AU - Philipp, S

AU - Reich, K

AU - Rosenbach, T

AU - Sammain, A

AU - Schlaeger, M

AU - Sebastian, M

AU - Sterry, W

AU - Streit, V

AU - Augustin, Matthias

AU - Erdmann, R

AU - Klaus, J

AU - Koza, J

AU - Müller, S

AU - Orzechowski, H D

AU - Rosumeck, S

AU - Schmid-Ott, G

AU - Weberschock, T

AU - Rzany, B

AU - Gesellschaft, Deutsche Dermatologische

AU - Dermatologen, Berufsverband Deutscher

PY - 2012

Y1 - 2012

N2 - Psoriasis vulgaris is a common and often chronic inflammatory skin disease. The incidence of psoriasis in Western industrialized countries ranges from 1.5 to 2%. Patients afflicted with severe psoriasis vulgaris may experience a significant reduction in quality of life. Despite the large variety of treatment options available, patient surveys have revealed insufficient satisfaction with the efficacy of available treatments and a high rate of medication non-compliance (Richards et al. in J Am Acad Dermatol 41(4):581-583, 1999). To optimize the treatment of psoriasis in Germany, the Deutsche Dermatologische Gesellschaft (DDG) and the Berufsverband Deutscher Dermatologen (BVDD) have initiated a project to develop evidence-based guidelines for the management of psoriasis first published in 2006 and now updated in 2011. The Guidelines focus on induction therapy in cases of mild, moderate, and severe plaque-type psoriasis in adults. This short version of the guidelines presents the resulting series of therapeutic recommendations, which were based on a systematic literature search and discussed and approved by a team of dermatology experts. In addition to the therapeutic recommendations provided in this short version, the full version of the guidelines includes information on contraindications, adverse events, drug interactions, practicality, and costs, as well as detailed information on how best to apply the treatments described (for full version please see Nast et al. in JDDG Suppl 2:S1-S104, 2011 or http://www.psoriasis-leitlinie.de ).

AB - Psoriasis vulgaris is a common and often chronic inflammatory skin disease. The incidence of psoriasis in Western industrialized countries ranges from 1.5 to 2%. Patients afflicted with severe psoriasis vulgaris may experience a significant reduction in quality of life. Despite the large variety of treatment options available, patient surveys have revealed insufficient satisfaction with the efficacy of available treatments and a high rate of medication non-compliance (Richards et al. in J Am Acad Dermatol 41(4):581-583, 1999). To optimize the treatment of psoriasis in Germany, the Deutsche Dermatologische Gesellschaft (DDG) and the Berufsverband Deutscher Dermatologen (BVDD) have initiated a project to develop evidence-based guidelines for the management of psoriasis first published in 2006 and now updated in 2011. The Guidelines focus on induction therapy in cases of mild, moderate, and severe plaque-type psoriasis in adults. This short version of the guidelines presents the resulting series of therapeutic recommendations, which were based on a systematic literature search and discussed and approved by a team of dermatology experts. In addition to the therapeutic recommendations provided in this short version, the full version of the guidelines includes information on contraindications, adverse events, drug interactions, practicality, and costs, as well as detailed information on how best to apply the treatments described (for full version please see Nast et al. in JDDG Suppl 2:S1-S104, 2011 or http://www.psoriasis-leitlinie.de ).

KW - Adult

KW - Diagnosis, Differential

KW - Germany

KW - Humans

KW - Quality of Life

KW - Patient Compliance

KW - Evidence-Based Medicine

KW - Patient Satisfaction

KW - Expert Testimony

KW - Clinical Protocols

KW - Skin/pathology

KW - Drug Therapy

KW - PUVA Therapy

KW - Psoriasis/diagnosis/epidemiology/physiopathology/therapy

KW - Adult

KW - Diagnosis, Differential

KW - Germany

KW - Humans

KW - Quality of Life

KW - Patient Compliance

KW - Evidence-Based Medicine

KW - Patient Satisfaction

KW - Expert Testimony

KW - Clinical Protocols

KW - Skin/pathology

KW - Drug Therapy

KW - PUVA Therapy

KW - Psoriasis/diagnosis/epidemiology/physiopathology/therapy

M3 - SCORING: Journal article

VL - 304

SP - 87

EP - 113

JO - ARCH DERMATOL RES

JF - ARCH DERMATOL RES

SN - 0340-3696

IS - 2

M1 - 2

ER -